Basal cell cancer is the most common form of skin cancer and its incidence is increasing worldwide. As a rule, surgery is the first choice for basal-cell carcinoma. However, for patients with low-risk superficial basal cell carcinomas, non-surgical medical therapy may be appropriate, said Eduardo Nagore, M.D. during a presentation at the European Academy of Dermatology and Venereology Congress last week in Paris. The author led a discussion about non-surgical therapeutic modalities for low-risk basal cell carcinomas.
Non-surgical therapy for basal cell cancer is suited to tumors around the eye, nose, mouth or ear where relapse can be devastating. The updated European guidelines for basal cell carcinomas treatment recommends imiquimod, photodynamic therapy, 5-fluorouracil, and cryosurgery as first-line treatments for superficial basal cell carcinomas, and all but imiquimod as second-line treatments for nodular basal cell carcinomas.
“While many people seem to be using non-surgical techniques, there has been a lack of good quality results from randomized controlled clinical trials,” Dr. Nagore siad. Any new treatment should be compared against surgery, which has the highest cure rate and lowest rate of recurrence, he said. In his presentation , he described the recent results from comparative randomized controlled trials.
Read the entire article here.